Brief: Janux Therapeutics Inc - Janx008 Data Shows No Crs Greater Than Grade 1 Observed In Any Cohort

Janux Therapeutics

26/02/2024 22:40

Feb 27 (Reuters) - Janux Therapeutics Inc  JANX.O :
    * JANUX THERAPEUTICS INC - JANX007 DATA SHOWS 83% (5/6) OF
SUBJECTS ACHIEVED PSA(50)DECLINES WITH FIRST STEP DOSE ≥ 0.2MG 
    * JANUX THERAPEUTICS INC - JANX008 DATA SHOWS NO CRS GREATER
THAN
GRADE 1 OBSERVED IN ANY COHORT
    * JANUX ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN
ONGOING
DOSE ESCALATION TRIALS FOR PSMAXCD3-TRACTR JANX007 IN MCRPC AND
EGFRXCD3-TRACTR JANX008 IN SOLID TUMORS
    * JANUX THERAPEUTICS INC - JANX007 DATA SHOWS 56% (10/18) OF
SUBJECTS ACHIEVED PSA(50)DECLINES WITH FIRST DOSE ≥ 0.1MG
    * JANUX THERAPEUTICS INC - JANX007 DATA SHOWS NO CRS GREATER
THAN
GRADE 2 WAS OBSERVED IN ANY COHORT
    * JANUX THERAPEUTICS INC - JANX008 DATA SHOWS NO TREATMENT
RELATED
SAES OR DLTS HAVE BEEN OBSERVED
    * JANUX THERAPEUTICS INC - ANTICIPATES PROVIDING AN UPDATE
ON
DOSES FOR EXPANSION IN SECOND HALF OF 2024

Source text for Eikon:  ID: 
Further company coverage:  JANX.O 

 ((Reuters.Briefs@thomsonreuters.com;))